Chai Discovery vs EvolutionaryScale (2026)
The two best governed companies in protein design, which matters because this is the one category in the index where the governance question is biosecurity rather than bias. EvolutionaryScale published its flagship model in a major peer reviewed journal, offers the widest access routes including holding the weights yourself, and publishes the most substantive position anywhere here on the risk that designing novel proteins creates. Chai releases named, versioned models with a documented history, quantifies its wet laboratory validation including how many targets were attempted and how many designs tested, and backs its governance position with a costly action rather than a statement. Both are unusually open for this field. Neither has a therapeutic established in humans, so read the excellent molecular evidence as exactly that.
- Models are named, versioned and released publicly with a documented history, and the underlying method is described specifically rather than as generative machine learning.
- Wet laboratory validation is quantified with its design stated, including how many targets were attempted and how many designs tested.
- The governance posture is the most complete in this category and is backed by a costly action rather than a policy statement.
- The flagship model appears in a major peer reviewed journal, so the method passed external review rather than a demonstration.
- The widest access in this category and the only route where a user can hold the weights, which changes the dependency entirely.
- It publishes a substantive position on the biosecurity risk that designing novel proteins creates, rather than generic principles.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Chai Discovery and EvolutionaryScale are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Chai Discovery | EvolutionaryScale |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2024 | Not recorded |
| Headquarters | San Francisco, California | New York, NY |
| Website | chaidiscovery.com | evolutionaryscale.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Chai Discovery its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Set against EvolutionaryScale, Chai Discovery grades higher on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards EvolutionaryScale its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and AI Governance and Bias Disclosure. Set against Chai Discovery, EvolutionaryScale grades higher on AI Safety and PHI Stewardship, Deployment Model and Data Residency and Commercial Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Chai Discovery or EvolutionaryScale?
On the axes where the AI Health Index separates them, Chai Discovery grades higher on Model Supply Chain Disclosure, and EvolutionaryScale grades higher on AI Safety and PHI Stewardship, Deployment Model and Data Residency and Commercial Transparency. EvolutionaryScale leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Chai Discovery and EvolutionaryScale differ most?
The widest separation the AI Health Index records between Chai Discovery and EvolutionaryScale is on Model Supply Chain Disclosure, where Chai Discovery grades A and EvolutionaryScale grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Chai Discovery and EvolutionaryScale grade the same?
The AI Health Index grades Chai Discovery and EvolutionaryScale the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
These two hold the strongest governance positions in a category where the governance question is biosecurity rather than bias, and that is the axis to compare them on rather than benchmark performance. Neither holds a located security attestation. Molecular evidence and clinical evidence are different things on both records: excellent laboratory validation exists and no therapeutic from either has been established in humans, so neither should be read as a clinical stage proposition. Neither publishes pricing, and the access models differ enough that a commercial comparison requires knowing which route you intend to take.